In the GO-RAISE study, which assessed the long-term effects of monthly subcutaneous golimumab (50 mg or 100 mg) versus placebo in patients with ankylosing spondylitis, the good clinical responses reported after 24 and 52 weeks were sustained at 104 weeks. Over 50% of patients in the treatment groups met the Assessment in SpondyloArthritis international Society (ASAS) criteria for 40% improvement from baseline and over 30% achieved partial remission. The safety profile was maintained from 24 weeks and is comparable to those other TNF inhibitors.
ORIGINAL RESEARCH PAPER
Braun, J. et al. Golimumab administered subcutaneously every 4 weeks in ankylosing spondylitis: 104-week results of the GO RAISE study. Ann. Rheum. Dis. doi:10.1136/ard.2011.154799
Rights and permissions
About this article
Cite this article
2-year results from the ankylosing spondylitis GO-RAISE study. Nat Rev Rheumatol 8, 2 (2012). https://doi.org/10.1038/nrrheum.2011.194
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrrheum.2011.194
